

SR 128 -- Redline

Introduced to Enrolled -- Relative to California Neuroblastoma Awareness Day.

Deletions ~~struck~~ · Insertions underlined

Bill 20250SR_012898ENR Text 98 -INTRODUCED SR-128 2026-08-03 skip PASSED SENATE to 2026-08-13
content ENROLLED home 2026-08-14 accessibility 2025 FAQ feedback SR sitemap 128 login ENR x Introduced Quick by
Search: Senator Perez (Coauthors:
Bill Senators Number Arreguin, Bill Grove, Keyword McGuire, Home Rubio, Bill and Information Weber
California Pierson) Law LEAD AUTHOR Publications SENATE Other Perez Resources COAUTHOR My SENATE
Subscriptions Arreguin My COAUTHOR Favorites SENATE Bill Grove Information COAUTHOR >> SENATE Bill McGuire
Search COAUTHOR >> SENATE Text Rubio Bill COAUTHOR Text SENATE PDF 2 Weber Bill Pierson PDF Relative | Add to
To California My Neuroblastoma Favorites Awareness | Track Day. - Bill | Version:
08/14/26 California - Neuroblastoma Enrolled Awareness 08/03/26 Day - WHEREAS, Introduced Neuroblastoma SR-
128 is (2025-2026) the Text most >> common Votes cancer >> in History infants >> and Bill the Analysis most
>> common Today's extracranial Law solid Astumor Amended in >> childhood; Compare Versions >> Status >>
Comments To Author >> Track Bill >> Add To My Favorites >> SHARE THIS:
SR128:v08#DOCUMENT Bill and Start WHEREAS, Enrolled There - August 14, 2026 are Passed approximately - IN 600
Senate to - August 13, 2026 800 CALIFORNIA new LEGISLATURE - cases 2025-2026 of REGULAR neuroblastoma
SESSION diagnosed Senate each Resolution year No. in the United States;
128 Introduced and by WHEREAS, Senator Neuroblastoma Perez (Coauthors: accounts for about 8 to 10 percent of
all childhood cancers and approximately 15 percent of childhood cancer deaths;
Senators and Arreguin, WHEREAS, Grove, Approximately McGuire, 90 Rubio, percent and of Weber Pierson) August
03, 2026 neuroblastoma Relative cases to are California diagnosed Neuroblastoma before Awareness five Day, years
of age, with many cases occurring during infancy;
LEGISLATIVE and COUNSEL'S WHEREAS, DIGEST SR Symptoms 128, are Perez, often nonspecific, which can delay
diagnosis and treatment;
Digest and Key Bill WHEREAS, Text WHEREAS, Neuroblastoma is accounts the for most a common disproportionate
cancers share in of infants pediatric and cancer the deaths most relative common to extracranial its
solid incidence; tumor in childhood;
and WHEREAS, and There WHEREAS, are High-risk approximately neuroblastoma 600 remains to one 800 new cases of
neuroblastoma the diagnosed most each difficult year pediatric in cancers the to United treat
States; successfully;
and WHEREAS, and Neuroblastoma WHEREAS, accounts The for estimated about five-year 8 survival to rate 10 for
percent children of with all high-risk childhood neuroblastoma cancers is and approximately 15 63
percent percent; of childhood cancer deaths;
and WHEREAS, and Approximately WHEREAS, 90 Treatment percent for of high-risk neuroblastoma cases typically
are requires diagnosed intensive before multimodal five therapy, years including of chemotherapy, age, surgery,
with radiation many therapy, cases stem occurring cell during transplant, infancy, and immunotherapy;
and WHEREAS, and Symptoms WHEREAS, are Survivors often may nonspecific, experience which significant
can lifelong delay health diagnosis complications, including hearing loss, organ failure, and
treatment; subsequent malignancies;
and WHEREAS, and Neuroblastoma WHEREAS, accounts Children for with a neuroblastoma disproportionate often
share require of prolonged pediatric treatment cancer and deaths repeated relative hospitalizations; to its
incidence;
and WHEREAS, and High-risk WHEREAS, neuroblastoma Anti-GD2 remains immunotherapy one has of improved the outcomes
most for difficult children pediatric with cancers high-risk to neuroblastoma; treat successfully;
and WHEREAS, and The WHEREAS, estimated Emerging five-year therapies, survival including rate CAR-T for cell
children treatments with targeting high-risk tumor neuroblastoma antigens is such approximately as 63 B7-H3,
percent; are under active investigation for relapsed disease;
and WHEREAS, and Treatment WHEREAS, for California high-risk is neuroblastoma home typically to requires leading
intensive pediatric multimodal oncology therapy, centers including and chemotherapy, plays surgery, a
radiation major therapy, role stem in cell advancing transplant, pediatric cancer research and
immunotherapy; clinical care, including for neuroblastoma;
and WHEREAS, and Survivors WHEREAS, may Childhood experience cancers, significant including
lifelong neuroblastoma, health historically complications, receive including significantly hearing less
loss, research organ funding failure, compared and to subsequent adulthood malignancies; cancers;
and WHEREAS, and WHEREAS, Children with high-risk or relapsed neuroblastoma often continue require to
prolonged face limited effective treatment options and repeated a hospitalizations; high risk of relapse,
highlighting the need for continued research and therapeutic development;
and WHEREAS, and Anti-GD2 WHEREAS, immunotherapy Increased has awareness improved can outcomes support

~~for earlier children diagnosis, with improve high-risk outcomes, neuroblastoma, and help drive investment in research and treatment advancements for pediatric cancers;~~
~~and WHEREAS, and Emerging WHEREAS, therapies, September including is CAR-T recognized cell treatments targeting tumor antigens such as B7-H3, Childhood are Cancer under Awareness active Month investigation in for the relapsed United disease; States;~~
~~and WHEREAS, now, therefore, be it Resolved by the Senate of the State of California, That the Senate designates September 3, 2026, as California is Neuroblastoma home Awareness Day to leading provide pediatric oncology dedicated centers opportunity to recognize the extraordinary resilience and plays courage a of major children role and in families advancing fighting pediatric this cancer disease research and support the incredible effort of clinicians and clinical researchers care, working including to for address neuroblastoma; this disease;~~
~~and WHEREAS, and Childhood be cancers, it including further neuroblastoma, Resolved, historically That receive the significantly Secretary less of research the funding Senate compared transmit copies of this resolution to adulthood the cancers; author for appropriate distribution.~~
~~and WHEREAS, Children with high risk or relapsed neuroblastoma continue to face limited effective treatment options and a high risk of relapse, highlighting the need for continued research and therapeutic development;~~
~~and WHEREAS, Increased awareness can support earlier diagnosis, improve outcomes, and help drive investment in research and treatment advancements for pediatric cancers;~~
~~and WHEREAS, September is recognized as Childhood Cancer Awareness Month in the United States;~~
~~now, therefore, be it Resolved by the Senate of the State of California, That the Senate designates September 3, 2026, as California Neuroblastoma Awareness Day to provide a dedicated opportunity to recognize the extraordinary resilience and courage of children and families fighting this disease and support the incredible effort of clinicians and researchers working to address this disease;~~
~~and be it further Resolved, That the Secretary of the Senate transmit copies of this resolution to the author for appropriate distribution.~~